Skip to main content
Article thumbnail
Location of Repository

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review

By Steven C Stoner and Megan M Dahmen


Bipolar disorder can be a devastating disease state for individuals with the disease and also for family members. Proper recognition and treatment is vital to the successful management of this disease state. Through increased community and practitioner awareness, along with efforts to increase awareness for proper assessment, the rate of diagnosed bipolar disorder is increasing. Recent years have brought about the introduction of several new medications with approved indications for the treatment of bipolar disorder. In addition to new agents, traditional mood stabilizing medications have also been released in different formulations to better enhance tolerability without jeopardizing efficacy. One particular product is extended-release divalproex sodium. In the following article, we review the clinical presentation of bipolar disorder, its epidemiology, and the pharmacokinetics and mechanism of action for divalproex. In addition, we specifically review the role of extended-release divalproex in bipolar disorder through a critical analysis of the currently available published primary literature

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2004). A study of the safety, effi cacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
    2. (2006). Abilify® package insert.
    3. (2004). Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services,
    4. (2005). Assessment of patient preference and side effects in patients switched from divalproex sodium delayed release to divalproex sodium extended release.
    5. (2002). Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
    6. (2002). Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers.
    7. (2006). Depakote® package insert.
    8. (2004). Diagnosing and treating comorbid (complicated) bipolar disorder.
    9. (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
    10. (2006). Effi cacy and tolerability of divalproex extended release in psychiatric patients.
    11. (2005). Effi cacy of valproate maintenance in patients with bipolar disorder and alcoholism. Arch Gen Psychiatry,
    12. (2004). Equetro® package insert.
    13. (2004). Extended-release divalproex sodium for mood stabilization.
    14. (2005). Extended-release divalproex sodium for patients with side effects from delayed-release divalproex sodium.
    15. (2005). Geodon® package insert.
    16. (2006). Lamictal® package insert.
    17. (2005). Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Molecular Psychiatry,
    18. (2006). Lithobid® package insert.
    19. (2006). Long-term prophylaxis in bipolar disorder.
    20. (2004). Mood stabilizers: protecting the mood…protecting the brain.
    21. (2003). Perceptions and impact of bipolar disorder: how far have we really come?
    22. (2003). Pharmacology of valproate.
    23. (2003). Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
    24. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition.
    25. (2002). Practice Guideline for the treatment of subjects with bipolar disorder (revision). Am J Psychiatry, 159(April Suppl):1–50.
    26. (2000). Psychiatric Association.
    27. (2006). Risperdal® package insert.
    28. (2003). Safety and effi cacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
    29. (2003). Screening for bipolar disorder in the community.
    30. (2003). Search for a common mechanism of mood stabilizers.
    31. (2006). Seroquel® package insert.
    32. (1999). The adverse effect profi le and effi cacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study.
    33. (2005). The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate. Medical Hypotheses,
    34. (2004). The expert consensus guideline series: treatment of bipolar disorder 2004. Postgraduate Medicine,
    35. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry,
    36. (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.
    37. (2004). Valproate decreases inositol biosynthesis.
    38. (2006). Zyprexa® package insert.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.